Literature DB >> 200263

Angiotensin I converting enzyme from human plasma.

J J Lanzillo, B L Fanburg.   

Abstract

The angiotensin I converting enzyme was purified 101 000-fold to homogeneity from human plasma by a combination of chromatographic and electrophoretic techniques. The enzyme is similar to other angiotensin I converting enzymes. It is an acidic glycoprotein consisting of a single polypeptide chain of molecular weight 140 000 with an isoelectric point of 4.6. The enzyme requires chloride ion for activity and is inhibited by ethylenediaminetetraacetic acid, angiotensin II, bradykinin, bradykinin potentiating factor nonapeptide, and 3-mercapto-2-D-methylpropanoyl-L-proline (SQ-14,225). The purified preparation cleaves bradykinin as well as angiotensin II and hippuryl-L-histidyl-L-leucine. Its specific activity with angiotensin I is 2.4 units per mg and with hippuryl-L-histidyl-L-leucine is 31.4 units per mg.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 200263     DOI: 10.1021/bi00644a015

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  10 in total

1.  Direct radioimmunoassay of angiotensin-converting enzyme in sera from patients with pulmonary diseases.

Authors:  K Hiwada; Y Inoue; Y Takada; A Hashimoto; H Akutsu; F Kitatani; T Kokubu
Journal:  Lung       Date:  1987       Impact factor: 2.584

2.  Increased angiotensin-converting enzyme in peripheral blood monocytes from patients with sarcoidosis.

Authors:  T Okabe; K Yamagata; M Fujisawa; J Watanabe; F Takaku; J J Lanzillo; B L Fanburg
Journal:  J Clin Invest       Date:  1985-03       Impact factor: 14.808

3.  Angiotensin-converting enzyme secretase is inhibited by zinc metalloprotease inhibitors and requires its substrate to be inserted in a lipid bilayer.

Authors:  S Parvathy; S Y Oppong; E H Karran; D R Buckle; A J Turner; N M Hooper
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

4.  Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific cytotoxic T lymphocytes.

Authors:  Y Nakagawa; T Takeshita; J A Berzofsky; H Takahashi
Journal:  Immunology       Date:  2000-09       Impact factor: 7.397

5.  Kinetic probes for inter-domain co-operation in human somatic angiotensin-converting enzyme.

Authors:  Olga E Skirgello; Peter V Binevski; Vladimir F Pozdnev; Olga A Kost
Journal:  Biochem J       Date:  2005-11-01       Impact factor: 3.857

6.  Monoclonal antibody against angiotensin-converting enzyme: its use as a marker for murine, bovine, and human endothelial cells.

Authors:  R Auerbach; L Alby; J Grieves; J Joseph; C Lindgren; L W Morrissey; Y A Sidky; M Tu; S L Watt
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

7.  Human lung angiotensin converting enzyme. Purification and antibody preparation.

Authors:  J Friedland; E Silverstein; M Drooker; C Setton
Journal:  J Clin Invest       Date:  1981-04       Impact factor: 14.808

8.  Angiotensin I-converting enzyme localization on cultured fibroblasts by immunofluorescence.

Authors:  K S Weinberg; W H Douglas; D R MacNamee; J J Lanzillo; B L Fanburg
Journal:  In Vitro       Date:  1982-04

9.  Characterization of a secretase activity which releases angiotensin-converting enzyme from the membrane.

Authors:  S Y Oppong; N M Hooper
Journal:  Biochem J       Date:  1993-06-01       Impact factor: 3.857

Review 10.  Angiotensin-converting enzyme and its clinical significance--a review.

Authors:  P R Studdy; R Lapworth; R Bird
Journal:  J Clin Pathol       Date:  1983-08       Impact factor: 3.411

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.